Double-blind, Randomized, Placebo-controlled Study on Efficacy, Safety and Tolerability of Ancrod in Patients With Sudden Sensorineural Hearing Loss (SSHL)
Phase of Trial: Phase I/II
Latest Information Update: 28 May 2019
Price : $35 *
At a glance
- Drugs Ancrod (Primary) ; Ancrod (Primary)
- Indications Sensorineural hearing loss; Sudden hearing loss
- Focus Therapeutic Use
- Sponsors Nordmark Arzneimittel
- 20 Dec 2018 Status changed from active, no longer recruiting to completed.
- 12 Oct 2018 This trial has been changed to Completed in Czech Republic (End date: 2018-09-18), according to European Clinical Trials Database.
- 25 Sep 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Oct 2018.